PMC:7426526 / 25857-26259 JSONTXT

{"project":"TEST0","denotations":[{"id":"32849491-131-138-3396341","span":{"begin":131,"end":134},"obj":"[\"26576938\"]"},{"id":"32849491-161-167-3396342","span":{"begin":398,"end":400},"obj":"[\"29845263\"]"}],"text":"In breast cancers, the expression of EpCAM is correlated to CSC-like phenotypes that promote formation of bone metastases in mice (480). In lung cancers, the expression of EpCAM is often associated with the expression of CD44 and CD166. Triple positive cells show increased clonogenicity, spheroid formation, self-renewal capacity, and show increased resistance to both 5-fluouracil and cisplatin (62)."}

{"project":"MyTest","denotations":[{"id":"32849491-26576938-34970721","span":{"begin":131,"end":134},"obj":"26576938"},{"id":"32849491-29845263-34970722","span":{"begin":398,"end":400},"obj":"29845263"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"In breast cancers, the expression of EpCAM is correlated to CSC-like phenotypes that promote formation of bone metastases in mice (480). In lung cancers, the expression of EpCAM is often associated with the expression of CD44 and CD166. Triple positive cells show increased clonogenicity, spheroid formation, self-renewal capacity, and show increased resistance to both 5-fluouracil and cisplatin (62)."}

{"project":"2_test","denotations":[{"id":"32849491-26576938-34970721","span":{"begin":131,"end":134},"obj":"26576938"},{"id":"32849491-29845263-34970722","span":{"begin":398,"end":400},"obj":"29845263"}],"text":"In breast cancers, the expression of EpCAM is correlated to CSC-like phenotypes that promote formation of bone metastases in mice (480). In lung cancers, the expression of EpCAM is often associated with the expression of CD44 and CD166. Triple positive cells show increased clonogenicity, spheroid formation, self-renewal capacity, and show increased resistance to both 5-fluouracil and cisplatin (62)."}